Valerio Therapeutics Finalizes Purchase of Etherna Immunotherapies

04:01 AM EDT, 10/12/2026 (MT Newswires) -- Valerio Therapeutics (ALVIO.PA) concluded the acquisition of healthcare technology company Etherna Immunotherapies, according to a Monday release. The biotechnology company acquired Etherna Immunotherapies for an enterprise value of 30 million euros, which was settled through cash and consideration shares. The acquisition is set to support Valerio Therapeutics' plan to develop its nucleic acid medicines portfolio.